Detalhe da pesquisa
1.
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial.
Br J Haematol
; 196(5): 1184-1193, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34951009
2.
Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma.
Blood
; 131(22): 2413-2425, 2018 05 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-29449275
3.
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.
Haematologica
; 105(6): 1604-1612, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31537689
4.
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia.
Haematologica
; 105(2): 448-456, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31371416
5.
Diffuse large B-cell lymphoma genotyping on the liquid biopsy.
Blood
; 129(14): 1947-1957, 2017 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28096087
6.
The genetics of nodal marginal zone lymphoma.
Blood
; 128(10): 1362-73, 2016 09 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27335277
7.
Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma.
Br J Haematol
; 185(2): 330-334, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29911350
8.
Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.
Br J Haematol
; 185(1): 156-159, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29785734
9.
Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
Expert Rev Hematol
; 11(5): 391-402, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29561706